
    
      PROTOCOL OUTLINE: Patients receive oral busulfan twice a day on days -9 to -6;
      cyclophosphamide IV over 1 hour on days -5 to -2; etoposide IV over 4 hours on days -5 to -3;
      and anti-thymocyte globulin IV twice a day on days -2 and -1 and days 1 and 2. Patients
      undergo allogeneic hematopoietic stem cell transplantation on day 0. Filgrastim (G-CSF) is
      administered subcutaneously beginning on day 1 and continuing until blood counts recover.
      Patients receive graft versus host disease prophylaxis with methotrexate IV on days 1, 3, 6,
      and 11 and cyclosporine IV over 1-4 hours (orally once the patients resumes eating) every 12
      hours (every 8 hours for pediatric patients) starting on or prior to day -3 and continuing up
      to 1 year.

      Patients are followed at days 28 and 100, at 6 months and 1 year, and then annually for 5
      years.
    
  